Familial Mediterranean fever in Russia: Experience of the Federal Rheumatology Center

The paper gives the experience of the V.A. Nasonova Research Institute of Rheumatology in identifying and managing patients with familial Mediterranean fever (FMF). Objective: to describe the features of the disease in patients with FMF in Russia and to compare them with the data obtained in the study of Turkish and Armenian populations with a high incidence of this disease. Patients and methods. The investigation enrolled 23 patients with a documented diagnosis of FMF who met the Turkish pediatric criteria (F. Yalcinkaya et al.) and/or the criteria described by A. Livnech et al. and had two identical mutations (homozygosity) or two different mutations (compound heterozygosity) in the MEFV gene. Among the patients there were 9 men and 14 women. The age of the patients at the time of treatment was 4.5 to 36 years. Their age at onset of FMF was 2 months to 15 years (mean age, 3.2±2.3 years). Results. The examination established that 18 (78.3%) patients were Armenians, 3 were representatives of the North Caucasus peoples (a Darghin woman, an Avar man, and an Ingush/Kabardian man), a man from mixed (Greek/Georgian) marriage, and a Russian woman whose ancestors were Armenian and Jewish. The most common manifestation of FMF were recurrent episodes of fever (22; 95.7%); abdominal pain with fever ranked second (19; 82.6%), followed by chest pain (11; 47.8%), locomotor apparatus lesion (16; 69.6%), and skin lesions (7; 30.4%). The episodes were accompanied by increased levels of acutephase markers in 100% of the patients. There were a high proportion of patients, in whom FMF was concurrent with other rheumatic and autoinflammatory diseases (juvenile chronic arthritis, chronic recurrent multifocal osteomyelitis, and acute rheumatic fever) (7; 30.4%). Twenty-two (95.6%) patients received colchicine; the tumor necrosis factor inhibitor etanercept was prescribed in 2 (8.7%) patients with comorbidity; there was a pronounced therapeutic effect. Conclusion. Although the majority of our patients were Armenians, the disease was also identified in those belonging to the peoples of the North Caucasus and Transcaucasia and in one Russian female patient. There has generally been a fairly typical picture of the disease. The considerable frequency of joint damage and the high proportion of patients with comorbid rheumatic diseases have engaged our attention. From a diagnostic point of view, of importance is the elevated level of acutephase markers during a disease attack, which in combination with the clinical and ethnic characteristics of patients allows the diagnosis of FMF to be suspected.

1. Fietta P. Autoinflammatory disease: the hereditary periodic fever syndromes. Acta Biomed. 2004 Aug;75(2):92-9.

2. Siegal S. Benign paroxysmal peritonitis. Ann Intern Med. 1945;23:1-21.

3. Reimann HA. Periodic disease A probable syndrome including periodic fever, benign paroxysmal peritonitis, cyclic neutropenia and intermittent arthralgia. J Am Med Assoc. 1948 Jan 24;136(4):239-44.

4. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997 Sep;17(1):25-31.

5. The International FMF Consortium. Ancient missense mutation in a new member of the RoRet gene family are likely to cause familial Mediterrnean fever. Cell. 1997 Aug 22;90(4):797-807.

6. Lidar M, Livnech A. Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med. 2007 Oct;65(9):318-24.

7. Амарян ГГ, Саркисян ТФ, Айрапетян АС. Семейная средиземноморская лихорадка у детей (периодическая болезнь): клинические и генетические аспекты. Методическое пособие. Ереван; 2012. [Amaryan GG, Sarkisyan TF, Airapetyan AS. Semeinaya sredizemnomorskaya likhoradka u detei (periodicheskaya bolezn'): klinicheskie i geneticheskie aspekty. Metodicheskoe posobie [Familial Mediterranean fever in children (periodic disease): clinical and genetic aspects. Methodical manual]. Erevan; 2012].

8. Федоров ЕС, Салугина СО, Кузьмина НН. Аутовоспалительные синдромы: что необходимо знать ревматологу. Современная ревматология. 2012;6(2): 49-59. [Fedorov ES, Salugina SO, Kuz'mina NN. Autoinflammatory syndromes: What a rheumatologist should know. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2012;6(2):49-59. (In Russ.)]. doi: 10.14412/1996-7012-2012-728

9. Федоров ЕС, Салугина СО, Кузьмина НН. Семейная средиземноморская лихорадка (периодическая болезнь): современный взгляд на проблему. Современная ревматология. 2013;7(1):24-30. [Fedorov ES, Salugina SO, Kuz'mina NN. Familial Mediterranean fever (a periodic disease): The present-day view of the problem. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(1):24-30. (In Russ.)]. doi: 10.14412/1996-7012- 2013-2363

10. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein interacts directly with caspase-1 to modulate IL-1-beta production. Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9982-7. Epub 2006 Jun 19.

11. Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibility for the target therapy. Br J Haematol. 2009 Sep;146(5):467-78. doi: 10.1111/j.1365- 2141.2009.07733.x. Epub 2009 May 14.

12. Bagci S, Toy B, Tuzun A, et al. Continue of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol. 2004 Aug;23(4):333-7. Epub 2004 May 1.

13. Schattner A, Lachmi M, Livenh A. Tumor necrosis factor in familial Mediterranean fever. Am J Med. 1991 Apr; 90(4):434-8.

14. Cobankara V, Fidan G, Turk T, et al. The prevalence of familial Mediterranean fever in the Turkish province of Denizli: a field study with a zero patient design. Clin Exp Rheumatol. 2004 Jul-Aug;22 (4 Suppl 34):S27-30.

15. Sarkisian T, Ajrapetian H, Beglarian A, et al. Familial Mediterranean fever in Armenian population. Georgian Med News. 2008 Mar;(156):105-11.

16. Daniels N, Shohat T, Brenner-Ullman A, et al. Familial Mediterranean fever: high gene frequency among the non-Ashkenazic and Ashkenazic Jewish population in Israel. Am J Med Genetic. 2005; 55:311-314.

17. Medllei-Hashim M, Serre JL, Corbani S, et al. Familial Mediterranean fever(FMF) in Lebanion and Jordan: a population genetic study and report of three novel mutation. Eur J Med Genet. 2005 Oct-Dec;48(4):412-20. Epub 2005 Jun 20.

18. Mattit H, Joma M, Al-Cheikh S, et al Familial Mediterranean fever in the Syrian population: gene mutation, frequencies, carrier rates and phenotype-genotype correlation. Eur J Med Genet. 2006 Nov-Dec;49(6): 481-6. Epub 2006 Apr 3.

19. Papandopulos VP, Giaglis S, Mitroulis I, Ritis K. The population genetics of familial Mediterranean fever: meta-analysis study. Ann Hum Genet. 2008 Nov;72(Pt 6):752-61. doi: 10.1111/j.1469-1809.2008.00471.x. Epub 2008 Aug 6.

20. Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the World. Arthritis Rheum. 2009 Oct 15;61(10):1447-53. doi: 10.1002/art.24458.

21. Migita K, Uehara R, Nakamura Y, et al Familial Mediterranean fever in Japan. Medicine (Baltimore). 2012 Nov;91(6):337-43. doi: 10.1097/MD.0b013e318277cf75.

22. La Regina M, Nucera G, Diaco M, et al Familial Mediterranean fever is no longer a rare disease in Italy. Eur J Hum Genet. 2003 Jan;11(1):50-6.

23. Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009 Apr;48(4):395-8. doi: 10.1093/rheumatology/ken509. Epub 2009 Feb 4.

24. Livnech A, Langevittz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997 Oct;40(10):1879-85.

25. Амрян ГГ. Периодическая болезнь у детей: клинико-генетические аспекты и современные подходы к лечению. Авто- реф. дисс. ... докт. мед. наук. Ереван; 2010. [Amryan GG Periodic disease in children: clinical and genetic aspects and modern approaches to the treatment. Autoref. diss. doct. med. sci. Erevan; 2010].

26. Ozen S, Bakkaloglu A, Yilmaz E, et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol. 2003 Sep; 30(9):2014-8.

27. Kalinich T, Haffer D, Niehues T, et al. Colchicune Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement. Pediatrics. 2007 Feb;119(2):e474-83. Epub 2007 Jan 22.

28. Ozdogan H, Ugurlu S. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol. 2017 Mar 31. doi: 10.1080/1744666X.2017.1313116. [Epub ahead of print].

29. Laskari K, Boura P, Dalekos GN, et al. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever. J Rheumatol. 2017 Jan;44(1):102-109. doi: 10.3899/ jrheum.160518

30. Akglu O, Kilik E, Kilik G, Ozgocmen S. Efficacy and safety of biologic treatments in Familial Mediterranean Fever. Am J Med Sci. 2013 Aug;346(2):137-41. doi: 10.1097/MAJ.0b013e318277083b.